Amgen is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. Co.'s products include: Enbrel® (etanercept), which is used in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis; and Prolia® (denosumab), which is used for the treatment of postmenopausal women with osteoporosis at high risk of fracture or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. We show 43 historical shares outstanding datapoints in our AMGN shares outstanding history coverage, used to compute AMGN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AMGN market cap history over the course of time is important for investors
interested in comparing AMGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AMGN versus a peer is one thing; comparing
AMGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AMGN can fluctuate over the course of history.
With this page we aim to empower investors researching AMGN by allowing them to research the AMGN market cap history. |
Video: The Importance of Market Cap
